The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors

Recruiting

• Conditions: Urinary System Carcinoma

• Registration Number: NCT06490211
• Lead Sponsor: Wuhan Union Hospital, China

Brief Summary

Obtain puncture or surgically removed tumor tissue samples from patients with urinary tract tumors and perform RNA-sequencing, Single-cell RNA-sequence, Spatial Transcriptomics, Proteomics, and Intratumoral Microbiome.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-20
• Status Verified: 2024-06
• Study First Submitted: 2024-06-30
• Study First Submitted QC: 2024-06-30
• Last Update Submitted: 2024-06-30
• Study First Posted: 2024-07-08
• Last Update Posted: 2024-07-08
• Primary Completion: 2026-11-20
• Study Completion: 2026-11-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026;
2. Aged > 18 years old;
3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion Criteria

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignant tumor other than urinary tract tumor;
4. Unclear pathological diagnosis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression-free survival	2 years

Trial Locations

Locations (1)

Union Hospital，Tongji Medical College，Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China